Hepatitis C and treatment with pegylated interferon and ribavirin.

Hepatitis C is a hepatotropic RNA virus with a propensity to cause chronic infection, causing a worldwide burden of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Both viral elimination and hepatocellular damage are thought to be immune mediated with T-helper and cytotoxic T-lymphocytes central to these events. A delay in the onset of adaptive immunity following infection indicates that a defect in the innate immune response may lead to viral persistence with a combination of other mechanisms subsequently contributing. Antiviral therapy based on interferon-alpha leads to resolution of disease in approximately 50% of patients. Specific anti-hepatitis C anti-viral drugs are being developed.